Chronic kidney disease (CKD) is a recognized risk multiplier for development of cardiovascular disease (CVD), with CVD events representing the leading cause of morbidity and mortality in patients with CKD. The nature of CKD as a risk state relates both to the nature of CKD and the antecedent development of CVD. In addition, patients with CKD have increased rates of multiple conventional cardiac risk factors. The essence of the relationship appears to be bidirectional, and therapy directed at improving natural history of chronic disease on one system generally improves prognosis in the other. Hence the term ‘cardiorenal syndrome’ (CRS) is used to describe the complex interrelationships between the two organ systems. While focus on therapeutic targets has been dominated by interest in neurohormonal mechanisms, little attention has been given to micronutrients and their potential effects in CRS. As renal function declines, cellular metabolism changes profoundly, and when artificial means of solute removal are initiated by peritoneal dialysis or hemodialysis, there are considerable shifts of many micronutrients that may affect cardiovascular health predominantly through the mechanism of increasing labile iron-dependent oxidative stress. Release of labile iron at the tissue level appears to be most important in acute CRS, whereas phosphate and sodium retention play more of a role in chronic CRS. Attention will be given to selected micronutrients which may call for novel assessments and intervention for optimal cardiorenal outcomes.

Keywords:
Cardiorenal syndrome, Chronic kidney disease, Acute kidney injury, Cardiovascular disease, Nutrition, Micronutrient
1.
McCullough PA: Why is chronic kidney disease the ‘spoiler’ for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725–728.
2.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–2169.
3.
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, for the Acute Dialysis Quality Initiative (ADQI) consensus group: Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010;31:703–711.
4.
Shah SV: Oxidants and iron in chronic kidney disease. Kidney Int Suppl 2004;S50–S55.
5.
Walker BL, Tiong JW, Jefferies WA: Iron metabolism in mammalian cells. Int Rev Cytol 2001;211:241–278.
6.
Richardson DR, Lane DJ, Becker EM, Huang ML, Whitnall M, Rahmanto YS, Sheftel AD, Ponka P: Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci USA 2010;107:10775–10782.
7.
Balla J, Vercellotti GM, Jeney V, Yachie A, Varga Z, Jacob HS, Eaton JW, Balla G: Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment. Antioxid Redox Signal 2007;9:2119–2137.
8.
Prakash M, Upadhya S, Prabhu R: Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. Clin Chim Acta 2005;360:194–198.
9.
Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, Marx JJ: Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002;32(suppl 1):36–41.
10.
Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000;15:1827–1834.
11.
Driss F, Vrtovsnik F, Katsahian S, Michel C, Baron G, Kolta A, Sedrati N, Mentré F, Mignon F, Cabantchik I, Grandchamp B: Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients. Nephron Clin Pract 2005;99:c63–c67.
12.
Espósito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32(suppl 1):42–49.
13.
Sengoelge G, Rainer V, Kletzmayr J, Jansen M, Derfler K, Födinger M, Hörl WH, Sunder-Plassmann G: Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. Kidney Int 2004;66:295–302.
14.
Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002;32(suppl 1):9–16.
15.
Lyseng-Williamson KA, Keating GM: Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009;69:739–756.
16.
Lele S, Shah S, McCullough PA, Rajapurkar M: Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention 2009;5:336–342.
17.
Baliga R, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999;31:971–997.
18.
Kell DB: Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;2:2.
19.
Moussavian MR, Slotta JE, Kollmar O, Menger MD, Gronow G, Schilling MK: Post-hypoxic cellular disintegration in glycine-preserved renal tubules is attenuated by hydroxyl radical scavengers and iron chelators. Langenbecks Arch Surg 2008;393:303–310.
20.
McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419–1428.
21.
Bellomo R, Auriemma S, Fabbri A, D’Onofrio A, Katz N, McCullough PA, Ricci Z, Shaw A, Ronco C: The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int J Artif Organs 2008;31:166–178.
22.
Elahi MM, Battula NR, Hakim NS, Matata BM: Acute renal failure in patients with ischemic heart disease: causes and novel approaches in breaking the cycle of self-perpetuating insults abrogated by surgery. Int Surg 2005;90:202–208.
23.
Diez C, Haneya A, Brünger F, Philipp A, Hirt S, Ruppecht L, Kobuch R, Keyser A, Hilker M, Puehler T, Schmid C: Minimized extracorporeal circulation cannot prevent acute kidney injury but attenuates early renal dysfunction after coronary bypass grafting. ASAIO J 2009;55:602–607.
24.
Ranucci M, Ballotta A, Kunkl A, De Benedetti D, Kandil H, Conti D, Mollichelli N, Bossone E, Mehta RH: Influence of the timing of cardiac catheterization and the amount of contrast media on acute renal failure after cardiac surgery. Am J Cardiol 2008;101:1112–1118.
25.
McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368–375.
26.
Del Duca D, Iqbal S, Rahme E, Goldberg P, de Varennes B: Renal failure after cardiac surgery: timing of cardiac catheterization and other perioperative risk factors. Ann Thorac Surg 2007;84:1264–1271.
27.
Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, Allison JJ: Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008;168:609–616.
28.
Adabag AS, Ishani A, Bloomfield HE, Ngo AK, Wilt TJ: Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials. Eur Heart J 2009;30:1910–1917.
29.
Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL: A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007;5:32.
30.
Brown JR, Block CA, Malenka DJ, O’Connor GT, Schoolwerth AC, Thompson CA: Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2009;2:1116–1124.
31.
Chinnaiyan KM, Alexander D, McCullough PA: Role of angiotensin II in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich) 2005;7:740–747.
32.
McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL, for the KEEP Investigators: Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007;167:1122–1129.
33.
Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA: Renal dysfunction and acceleration of coronary disease. Heart 2004;90:961–966.
34.
McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Whaley-Connell AT, Brenner RM, Bakris GL, KEEP Investigators: Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J 2008;156:277–283.
35.
McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004;17:205–215.
36.
Tintut Y, Demer LL: Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol 2001;12:555–560.
37.
McCullough PA, Agrawal V, Danielewicz E, Abela GS: Accelerated atherosclerotic calcification and Mönckeberg’s sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1585–1598.
38.
Bhakta M, Bruce C, Messika-Zeitoun D, Bielak L, Sheedy PF, Peyser P, Sarano M: Oral calcium supplements do not affect the progression of aortic valve calcification or coronary artery calcification. J Am Board Fam Med 2009;22:610–616.
39.
Byrne FN, Kinsella S, Murnaghan DJ, Kiely M, Eustace JA: Lack of correlation between calcium intake and serum calcium levels in stable haemodialysis subjects. Nephron Clin Pract 2009;113:c162–c168.
40.
McCullough PA, Chinnaiyan KM: Annual progression of coronary calcification in trials of preventive therapies: a systematic review. Arch Intern Med 2009;169:2064–2070.
41.
Guérin AP, Pannier B, Métivier F, Marchais SJ, London GM: Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2008;17:635–641.
42.
Bays HE: ‘Sick fat’, metabolic disease, and atherosclerosis. Am J Med 2009;122(suppl): S26–S37.
43.
Bagshaw SM, Cruz DN: Fluid overload as a biomarker of heart failure and acute kidney injury. Contrib Nephrol 2010;164:54–68.
44.
Kimura G, Dohi Y, Fukuda M: Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens Res 2010;33:515–520.
45.
Ritz E, Koleganova N, Piecha G: Role of sodium intake in the progression of chronic kidney disease. J Ren Nutr 2009;19:61–62.
46.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034–2047.
47.
Stamler J: The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nutr 1997;65(suppl):626S–642S.
48.
He FJ, MacGregor GA: Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004;CD004937.
49.
Hooper L, Bartlett C, Davey SG, Ebrahim S: Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev 2004;CD003656.
50.
Dracup K, Baker DW, Dunbar SB, Dacey RA, Brooks NH, Johnson JC, Oken C, Massie BM: Management of heart failure. II. Counseling, education, and lifestyle modifications. JAMA 1994;272:1442–1446.
51.
Penne EL, Levin NW, Kotanko P: Improving volume status by comprehensive dietary and dialytic sodium management in chronic hemodialysis patients. Blood Purif 2010;30:71–78.
52.
Stein G, Sperschneider H, Koppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 1985;3:52–62.
53.
Suliman ME, Lindholm B, Bárány P, Qureshi AR, Stenvinkel P: Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial 2007;20:523–529.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.